Replies to post #23520 on The Rising Influence of Rising Affluence

[DewDiligence]

PCVX—…the revelation of an additional competitor with a similar or even superior platform who's well funded, far more clinically advanced and with a major biopharma partner blows up the investment thesis in PCVX.

I would caution that, as a private company, Affinivax has not had to file a 10-K, disclosing whatever warts there might be in the product or the business plan. Until there is evidence to the contrary, I consider PCVX’s main impediment to eventual commercial success to be PFE, not Astellas/Affinivax.

I wonder if Vaxcyte mgt felt pressure to IPO fearing with every advance by Affinivax they would look less attractive to investors.

That makes sense; on the other hand, PCVX left money on the table insofar as they could surely have IPOd at a higher valuation if they had waited until now to do so.